The Pharma Data

OCTOBER 15, 2020

a leading biotechnology company developing small molecule therapeutics based on its proprietary uSMITE platform of targeted protein degradation technology, today announced that the company’s internal program to develop selective degraders that target key proteins within the TRK family has been published by the Journal of Medicinal Chemistry.

Targeted Protein Degradation 40

Targeted Protein Degradation Small Molecule Science Disease 40

The Pharma Data

DECEMBER 21, 2020

Targeted protein degradation (TPD) is an approach whereby the body’s natural process for degrading proteins is diverted using small molecule drugs to eliminate disease-causing proteins. . TOKYO and CAMBRIDGE, England , Dec. No further financial details are disclosed. ” About Sosei Heptares.

Targeted Protein Degradation 40

Targeted Protein Degradation Small Molecule Structure Based Drug Design (SBDD) Drugs 40

The Pharma Data

SEPTEMBER 25, 2020

. Monte Rosa Therapeutics has raised $96m in Series B financing to support further develop of its pipeline of small-molecule protein degraders. The company, which was originally formed as a spinout from Cancer Research UK-funded research at the Institute of Cancer Research, specialises in targeted protein degradation.

Targeted Protein Degradation 40

Targeted Protein Degradation Small Molecule Clinical Development Disease 40

The Pharma Data

DECEMBER 15, 2020

Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation using its PROTAC ® Discovery Engine, today announced the pricing of an underwritten public offering of 5,714,286 shares of its common stock at a price of $70.00 NEW HAVEN, Conn., Forward-Looking Statements.

Targeted Protein Degradation 40

Targeted Protein Degradation Engineering Clinical Trials Disease 40

Drug Hunter

AUGUST 21, 2023

Recent promising results from a Phase 2/3 trial support the use of a single oral dose of brain-penetrant acoziborole (SCYX-7158) for HAT treatment. The need to achieve CNS target coverage with a single dose makes the HAT field an excellent source of case studies for improving brain penetration, with three examples noted below.

Drugs 206

Drugs Disease Targeted Protein Degradation Screening Hits 206

Drug Target Review

JULY 5, 2024

A regenerative approach to the treatment of multiple sclerosis. Her research interest is in the neuroscience and oncology areas using both traditional and targeted protein degradation approaches. [link] Madhavan M, et al. Induction of myelinating oligodendrocytes in human cortical spheroids. Nat Methods.

Targeted Protein Degradation 64

Targeted Protein Degradation Drugs Disease FDA Approval 64

The Pharma Data

SEPTEMBER 15, 2020

.” Trilo Therapeutics: Trilo Therapeutics is focused on the discovery of novel inhibitors of protein-protein interactions for therapeutic purposes. Our Degradomer® class of targeted protein degraders expands on the Trilomer® concept, allowing highly specific degradation of disease-causing proteins.

Targeted Protein Degradation 52

Targeted Protein Degradation Molecular Biology Science Small Molecule 52

Elrig

MARCH 22, 2023

These fields are moving at remarkable speed and have huge potential to transform treatments. Right now, targeted protein degradation is a critical focus topic across both industry and academia. But it can be tricky for many in the scientific community to keep pace,” said Sanj Kumar, CEO, ELRIG.

Targeted Protein Degradation 40

Targeted Protein Degradation Science Disease Laboratories 40

Covalent Modifiers

JANUARY 7, 2025

Second, we highlight various recent examples of protein functionalization using NASA/ArNASA chemistry, such as visualization of membrane proteins including therapeutically important G-protein coupled receptors, gel-based ligand screening assays, photochemical control of protein activity, and targeted protein degradation.

Targeted Protein Degradation 147

Targeted Protein Degradation Pharmaceuticals Research Treatment 147

LifeSciVC

FEBRUARY 5, 2025

However, in recent years, huge leaps have been made in drug discovery ranging from novel technologies unearthing new techniques for small molecule development to new modalities like targeted protein degradation that are beginning to open the door to a promising wave of transcription factor-directed therapeutic candidates.

Small Molecule 67

Small Molecule Targeted Protein Degradation Regulations Disease 67